BLUE bluebird bio, Inc. Stock Quote

BLUE [NASD]

Index	-	P/E	-	EPS (ttm)	-8.01	Insider Own	1.50%	Shs Outstand	73.69M	Perf Week	-3.27%
Market Cap	287.73M	Forward P/E	-	EPS next Y	-2.42	Insider Trans	-2.55%	Shs Float	70.62M	Perf Month	31.01%
Income	-563.30M	PEG	-	EPS next Q	-1.24	Inst Own	89.80%	Short Float	17.84%	Perf Quarter	-16.19%
Sales	4.70M	P/S	61.22	EPS this Y	9.50%	Inst Trans	6.70%	Short Ratio	2.06	Perf Half Y	-62.16%
Book/sh	3.57	P/B	1.16	EPS next Y	44.80%	ROA	-	Target Price	7.33	Perf Year	-79.48%
Cash/sh	3.04	P/C	1.36	EPS next 5Y	-	ROE	-	52W Range	2.87 - 21.16	Perf YTD	-58.56%
Dividend	-	P/FCF	-	EPS past 5Y	-2.90%	ROI	-157.90%	52W High	-79.77%	Beta	1.33
Dividend %	-	Quick Ratio	-	Sales past 5Y	-9.90%	Gross Margin	-	52W Low	49.39%	ATR	0.55
Employees	518	Current Ratio	1.80	Sales Q/Q	111.10%	Oper. Margin	-	RSI (14)	55.25	Volatility	11.63% 16.02%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	8.60%	Profit Margin	-	Rel Volume	0.65	Prev Close	4.14
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 09 AMC	Payout	-	Avg Volume	6.11M	Price	4.28
Recom	3.20	SMA20	14.09%	SMA50	15.89%	SMA200	-45.25%	Volume	3,986,338	Change	3.38%

Apr-06-22

Downgrade

Cowen

Outperform → Market Perform

Mar-07-22

Downgrade

Barclays

Equal Weight → Underweight

Nov-08-21

Reiterated

Wells Fargo

Equal Weight

$25 → $16

Nov-08-21

Reiterated

Wedbush

Neutral

$22 → $11

Nov-08-21

Reiterated

RBC Capital Mkts

Sector Perform

$26 → $14

Nov-08-21

Reiterated

Canaccord Genuity

Hold

$20 → $15

Nov-08-21

Reiterated

Barclays

Equal Weight

$20 → $13

Nov-08-21

Downgrade

Morgan Stanley

Equal-Weight → Underweight

$11

Nov-08-21

Downgrade

Goldman

Neutral → Sell

$23 → $10

Aug-10-21

Resumed

William Blair

Mkt Perform

Aug-10-21

Downgrade

Wells Fargo

Overweight → Equal Weight

$60 → $25

Aug-10-21

Downgrade

Goldman

Buy → Neutral

$63 → $23

Aug-10-21

Downgrade

Canaccord Genuity

Buy → Hold

Aug-09-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

Jul-01-21

Downgrade

Berenberg

Buy → Hold

$35

Mar-10-21

Upgrade

Mizuho

Neutral → Buy

$34 → $69

Feb-17-21

Downgrade

JP Morgan

Overweight → Neutral

$76 → $39

Feb-16-21

Downgrade

William Blair

Outperform → Mkt Perform

Feb-16-21

Downgrade

Wedbush

Outperform → Neutral

Feb-16-21

Downgrade

BofA Securities

Buy → Neutral

Jun-23-22 11:30AM	Is Now a Good Time to Buy This Biotech Stock? Motley Fool
Jun-18-22 10:15AM	Did Bluebird Bio Stock Just Get a New Lease on Life? Motley Fool
Jun-17-22 12:03PM	Why Bluebird Bio Skyrocketed Today Motley Fool +16.34%
Jun-14-22 01:55PM	Why Bluebird Bio Stock Stumbled Today Motley Fool -16.16%
Jun-13-22 02:25PM	Bluebird Bio Stock Set for Largest One-Day Gain in Eight Years Barrons.com +14.48%
01:27PM	Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive Benzinga
01:27PM	FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy Zacks
12:50PM	Bluebird stock soars on FDA committee news, despite overall market woes American City Business Journals
08:20AM	Bluebird's stock is up 70% after FDA committee voted in favor of the company's gene therapies last week MarketWatch
07:54AM	bluebird bio (Finally) Nears Approval. What's Next? TheStreet.com
06:48AM	FDA Advisory Committee Backs Bluebird Bio's Blood Disorder Gene Therapy Benzinga
Jun-10-22 03:42PM	In crucial win, bluebird nabs a second FDA committee endorsement American City Business Journals
03:30PM	FDA Committee Recommends bluebird's (BLUE) CALD Therapy Zacks
03:18PM	FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions Business Wire
01:03PM	An FDA Approval Could Send This Stock Soaring by August Motley Fool
08:29AM	FDA committee votes in favor of Bluebird's gene therapy for rare neurodegenerative disease MarketWatch
Jun-09-22 08:21PM	FDA advisers vote a unanimous 'yes' on one of bluebird's two gene therapies American City Business Journals
06:17PM	Bluebird Bio Sees Road to Revival After Gene-Therapy Misfires Bloomberg
06:14PM	FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy Business Wire
07:29AM	Bluebird's stock is halted ahead of FDA meeting for its gene therapy candidates MarketWatch
07:05AM	bluebird bio stock trading halted today June 9th and tomorrow June 10th Business Wire
Jun-08-22 01:21PM	bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy Zacks
11:30AM	Bluebird (BLUE) Down 6.2% Since Last Earnings Report: Can It Rebound? Zacks
Jun-07-22 01:32PM	FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another Benzinga +21.14%
08:36AM	bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting Business Wire
May-19-22 06:00PM	7 Cheap Biotech Stocks to Buy Now InvestorPlace
May-13-22 10:32AM	These 5-Stock Samplers Have Gotten Whacked. And That's OK Motley Fool +5.93%
May-09-22 06:25PM	Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates Zacks -10.72%
04:05PM	bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress Business Wire
Apr-27-22 03:03PM	Will Bluebird Bio (BLUE) Report Negative Q1 Earnings? What You Should Know Zacks
Apr-22-22 03:29PM	Why bluebird bio (BLUE) Stock Plunged 60% Year to Date? Zacks
Apr-17-22 11:15AM	Where Will Bluebird Bio Be in 1 Year? Motley Fool
Apr-15-22 11:30AM	Is Bluebird Bio a Buy? Motley Fool
Apr-08-22 06:57AM	Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks InvestorPlace
Apr-06-22 12:36PM	bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn Zacks
Apr-05-22 12:14PM	Gene therapy developer bluebird bio to cut 30% of staff American City Business Journals
08:59AM	Bluebird bio to lay off nearly one-third of its employees as part of restructuring MarketWatch
07:21AM	UPDATE 1-Bluebird bio to slash 30% of workforce as part of restructuring Reuters
07:00AM	bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US Business Wire
Mar-29-22 07:00AM	Blue Thunder Partners with Windfall Geotek for AI Targeting Solutions over Its Muus Property, Quebec Newsfile +5.26%
Mar-24-22 07:00AM	Blue Thunder Completes Option Agreement for 100% Interest in the Tectonic Property, On-Trend with Major Gold Deposits in the Chibougamau District, Quebec Newsfile
Mar-23-22 02:41PM	2seventy bio discloses job cuts after split from bluebird American City Business Journals
Mar-10-22 05:01PM	Why Bluebird Bio Stock Is Sinking This Week Motley Fool -7.44%
Mar-07-22 02:58PM	Why Bluebird Bio Stock Is Sinking Today Motley Fool -11.00%
12:00PM	Cash-crunched bluebird bio loses CFO American City Business Journals
Mar-04-22 05:45PM	Bluebird Bio (BLUE) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:31PM	bluebird bio Reports Fourth Quarter and Full Year 2021 Financial Results, Highlights Operational Progress and Provides Corporate Update Business Wire
Feb-28-22 05:45PM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates Zacks
Feb-17-22 10:52AM	The Petri Dish: 2seventy rounds out C-suite, Moderna goes global American City Business Journals -5.08%
Feb-15-22 03:01PM	Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks +5.77%
Feb-01-22 09:38PM	AGF Investments LLC Buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The ... GuruFocus.com
Jan-26-22 08:00AM	Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer GlobeNewswire
Jan-20-22 05:36AM	The Petri Dish: Thermo Fisher taps Olaris, bluebird drugs delayed American City Business Journals -8.21%
Jan-19-22 11:29AM	bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down Zacks
Jan-18-22 07:00AM	bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD) Business Wire -9.39%
Jan-14-22 08:37AM	Why Bluebird Bio Stock Is Sinking This Week Motley Fool
Jan-13-22 05:45AM	Post-split bluebird bio plans to launch 3 gene therapies in 2 years American City Business Journals
Jan-11-22 12:11PM	Bluebird bio Lays Out Planned Updates Ahead Of J.P. Morgan Healthcare Conference Benzinga
07:00AM	bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-05-22 08:00AM	bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-04-22 03:33PM	UAB researchers target potential treatment for sickle cell disease American City Business Journals
Dec-23-21 06:35AM	The Petri Dish: Biogen slashes Alzheimer's drug price, bluebird faces clinical hold American City Business Journals
Dec-20-21 11:15AM	Why Bluebird Bio Stock Is Plunging Today Motley Fool
09:13AM	Why Are Bluebird Bio Shares Trading Lower Today? Benzinga
08:38AM	UPDATE: Bluebird Bio announces partial clinical hold for patients under 18 in sickle cell gene therapy program MarketWatch
08:10AM	Bluebird Bio announces partial clinical hold for patients under 18 in sickle cell gene therapy program MarketWatch
08:00AM	bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program Business Wire
Dec-17-21 06:35PM	bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor Business Wire +13.34%
Dec-15-21 10:00AM	Bluebird (BLUE) Loses 20.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks
Dec-12-21 05:04PM	New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM Business Wire
Dec-11-21 10:33AM	New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for -thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels Business Wire
Dec-09-21 07:38PM	Nationwide Variable Insurance Trust Buys Ollie's Bargain Outlet Holdings Inc, Grocery Outlet ... GuruFocus.com -6.20%
Nov-22-21 06:54AM	Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA Benzinga
06:30AM	bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with -thalassemia Who Require Regular Red Blood Cell Transfusions Business Wire
Nov-17-21 02:33PM	After split, bluebird bio's new CEO looks to 'regain confidence' American City Business Journals
Nov-12-21 10:50AM	Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy Zacks
Nov-08-21 05:30PM	Why Bluebird Bio Stock Plunged Today Motley Fool -18.57%
Nov-07-21 07:12AM	Could The bluebird bio, Inc. (NASDAQ:BLUE) Ownership Structure Tell Us Something Useful? Simply Wall St.
Nov-05-21 08:25AM	Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates Zacks -19.42%
07:05AM	bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress Business Wire
07:00AM	Cambridge gene therapy firm bluebird bio to move to Somerville American City Business Journals
06:58AM	bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row Business Wire
Nov-04-21 04:35PM	Bluebird bio completes spinout of oncology business 2seventy bio American City Business Journals
09:00AM	bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition Business Wire
07:00AM	bluebird bio Completes Planned Business Separation Business Wire
Oct-27-21 03:04PM	Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks +5.30%
Oct-25-21 02:44PM	Hedge Funds Arent Crazy About bluebird bio Inc (BLUE) Anymore Insider Monkey
Oct-21-21 09:59AM	Bluebird Bio To Withdraw Marketing Of Skysona Gene Therapy In Europe Benzinga
Oct-18-21 09:00AM	bluebird bio Sets Record Date and Distribution Date for Planned Business Separation Business Wire
Oct-08-21 04:54PM	bluebird bio Provides Update on Upcoming Planned Business Separation Business Wire
Sep-22-21 07:03AM	Bluebird Bio Files US Application For -thalassemia Gene Therapy Benzinga
Sep-21-21 04:15PM	bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With -thalassemia Who Require Regular Red Blood Cell Transfusions Business Wire
Sep-13-21 08:00AM	2seventy bio Announces Upcoming Investor Events Business Wire
Sep-08-21 11:30AM	Why Is Bluebird (BLUE) Down 13.3% Since Last Earnings Report? Zacks
07:30AM	bluebird bio Secures $75 Million in Private Placement Equity Financing Business Wire
Sep-07-21 04:05PM	bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events Business Wire
Aug-13-21 10:50PM	BLUEBIRD BIO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE Business Wire
Aug-11-21 01:22AM	bluebird bio, Inc. (NASDAQ:BLUE) Analysts Just Trimmed Their Revenue Forecasts By 15% Simply Wall St.
Aug-09-21 04:04PM	Bluebird Stock Crashes To 7-Year Low After FDA Pauses Gene Therapy Test Investor's Business Daily -27.45%
12:38PM	Why Bluebird Bio Stock Is Crashing Today Motley Fool

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klima Thomas J	Chief Commercial Officer	Jun 03	Sale	3.07	3,753	11,535	71,439	Jun 07 04:16 PM
Cole Jason	Chief Operating and	Jan 11	Sale	9.64	3,387	32,659	186,188	Jan 12 09:15 PM
Leschly Nick	Director	Jan 11	Sale	9.64	5,068	48,869	281,330	Jan 12 09:15 PM
Obenshain Andrew	President and CEO	Jan 11	Sale	9.64	4,683	45,156	246,696	Jan 12 09:15 PM
Whitten Jessica	Chief Accounting Officer	Jan 11	Sale	9.64	279	2,690	49,413	Jan 12 09:16 PM
Whitten Jessica	Chief Accounting Officer	Jan 10	Sale	9.40	130	1,222	49,692	Jan 12 09:16 PM
Obenshain Andrew	President and CEO	Jan 10	Sale	9.36	3,042	28,467	251,379	Jan 12 09:15 PM
Leschly Nick	Director	Jan 10	Sale	9.40	2,369	22,274	286,398	Jan 12 09:15 PM
Cole Jason	Chief Operating and	Jan 10	Sale	9.40	1,584	14,893	189,575	Jan 12 09:15 PM
Whitten Jessica	Chief Accounting Officer	Jan 05	Sale	10.44	2,984	31,143	49,822	Jan 07 04:28 PM
Obenshain Andrew	President and CEO	Dec 07	Sale	10.18	832	8,469	254,421	Dec 09 04:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience